Century Therapeutics (NASDAQ:IPSC) Downgraded to Sell Rating by Wall Street Zen

Century Therapeutics (NASDAQ:IPSC) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Several other research analysts also recently commented on the stock. Leerink Partners set a $2.00 price objective on shares of Century Therapeutics and gave the company a “market perform” rating in a research report on Friday, March 13th. TD Cowen began coverage on shares of Century Therapeutics in a report on Wednesday, February 25th. They set a “buy” rating for the company. HC Wainwright boosted their price objective on shares of Century Therapeutics from $2.00 to $5.00 and gave the stock a “buy” rating in a research note on Tuesday. Piper Sandler boosted their price objective on shares of Century Therapeutics from $2.00 to $4.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Finally, Zacks Research cut shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 12th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $4.25.

Century Therapeutics Stock Down 1.8%

Shares of NASDAQ:IPSC opened at $2.22 on Friday. Century Therapeutics has a 12-month low of $0.44 and a 12-month high of $3.04. The business has a 50 day moving average of $2.30 and a 200-day moving average of $1.48. The stock has a market cap of $399.73 million, a PE ratio of -15.86 and a beta of 1.66.

Century Therapeutics (NASDAQ:IPSC) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Equities research analysts expect that Century Therapeutics will post -0.63 earnings per share for the current year.

Insider Buying and Selling at Century Therapeutics

In related news, insider Gregory Russotti sold 10,076 shares of the company’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $2.55, for a total value of $25,693.80. Following the sale, the insider owned 515,427 shares in the company, valued at $1,314,338.85. This represents a 1.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 17,921 shares of company stock worth $45,458 in the last quarter. 4.37% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Century Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Prudential Financial Inc. purchased a new stake in Century Therapeutics in the 2nd quarter valued at about $25,000. Qube Research & Technologies Ltd purchased a new stake in Century Therapeutics in the 2nd quarter valued at about $38,000. Raymond James Financial Inc. bought a new position in shares of Century Therapeutics during the 2nd quarter valued at approximately $51,000. AQR Capital Management LLC grew its position in shares of Century Therapeutics by 358.9% during the 1st quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock valued at $53,000 after acquiring an additional 86,875 shares during the period. Finally, Bank of America Corp DE grew its position in shares of Century Therapeutics by 109.1% during the 4th quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock valued at $67,000 after acquiring an additional 34,466 shares during the period. Institutional investors and hedge funds own 50.20% of the company’s stock.

Key Century Therapeutics News

Here are the key news stories impacting Century Therapeutics this week:

• Positive Sentiment: Seeking Alpha publishes a speculative Buy thesis highlighting Century’s pivot to autoimmune CAR cells and CNTY‑813 (Type 1 diabetes) as the main value driver; the piece also notes management cut quarterly cash burn (from ~$35M to ~$20M) and extended runway to Q1 2028 — positive for execution and optionality. Century Therapeutics: A Biotech With Interesting Optionality Opportunities
• Positive Sentiment: HC Wainwright reiterated a Buy rating and $5 price target and published detailed EPS trajectories showing multi‑year losses but continued coverage — an analyst endorsement that can support the stock if pipeline milestones progress. MarketBeat: Century Therapeutics analyst coverage
• Neutral Sentiment: Short‑interest report shows effectively zero reported short interest and a 0.0 days‑to‑cover — likely a data artifact or low reported shorting activity; not a clear signal for immediate directional pressure.
• Negative Sentiment: Seeking Alpha and company disclosures note a materially dilutive PIPE (cited as ~134% dilution) — significant dilution can weigh on the stock and caps upside until the market sees meaningful clinical progress or revenue potential. Century Therapeutics: A Biotech With Interesting Optionality Opportunities

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.